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Poster Session-II 125alemtuzumab (a single subcutaneous dose on day –6). CsA was ta-
pered off on day 56 in the absence of GVHD. RIC protocol consisted
of fludarabine (30 mg/m2 x 4 days on days -5 to -2) and IV Busulphan
(3.2 mg/KBW x 2 days on days -3 and -2) with or without 200cGY of
TBI. Median follow-up of survivors was 24 months (range 15–48).
The median age at transplant was 52 years (range 33–64) and 15
pts. (42%) had significant co-morbidities (score of $3 using
HCT-specific index). 34 pts.(94%) had high-risk malignancies.
The source of hematopoietic cells was: peripheral blood, 31; and
bone marrow, 5. The cumulative incidence of relapse, non-relapse
mortality (NRM), progression-free and overall survivals at 1-year
were 19% (95% CI 10–38), 28% (95% CI 16–48), 53% (95% CI
35–67) and 61%(95% CI 43–75), respectively and no significant dif-
ferences were observed in two cohorts. The major cause of NRM was
infectious complications. Lymphocyte recovery at 30, 60 and 90 days
was significantly faster in the cohort 2, no differences were noted at
later time points (6, 9 and 12 months). The data on hematopoietic
recovery, engraftment and GVHD related parameters are summa-
rized in table 1.
Table 1: Hematopoietic recovery, engraftment, acute and
chronic GVHD in patients undergoing unrelated trans-
plantation using alemtuzumab based GVHD prophylaxis
Cohort 1 - Cohort 2 - P valueCharacteristics pWhole study
atients (n536)
a
6lemtuzumab
0mg(n517)
a
3lemtuzumab
0 mg (n519)
(cohort 1 vs.
cohort 2)Median days to
neutrophil recovery
(range)19 (12–29) 20 (15–29) 16 (12–22) 0.001Median days to platelet
recovery(range)13 (9–33) 14 (10–33) 11 (9–24) 0.10Median % donor cells
on day 30 (range)98 (52–100) 98 (52–100) 99 (76–100) 0.89Median % donor cells on
day 60 (range)98 (8–100) 99 (8–100) 98 (87–100) 0.14Median % donor cells
on day 120 (range)98 (5–100) 96 (5–100) 98 (73–100) 0.39Graft failure (Primary/
Late)2/2 1/1 1/1 1.00Median days to onset
of acute GVHD (range)40 (9–168) 46 (9–89) 38 (15–168) 1.00Cumulative incidence
of $ grade 2 acute
GVHD (95% CI)
@ 200 days
58% (44–77) 59% (39–90) 58 (39–87) 0.98Median days to onset
of chronic GVHD (range)
153 (101–541) 144 (101–369) 174 (102–541) 0.67Cumulative incidence of
chronic GVHD
(95% CI) @ 1-year
42% (28–64) 38% (19–72) 47% (28–80) 0.56Of note, no cases of grade 4 acute GVHD, steroid refractory acute
GVHD or severe chronic GVHD (using NIH consensus criteria on
global severity of chronic GVHD) in any of the cohorts. Our data
suggest that a low dose of alemtuzumab (30 mg) with CsA is an effec-
tive GVHD prophylaxis for the prevention of severe acute and
chronic GVHD with acceptable risk of relapse in the setting of
RIC for MUD transplantation and warrants further studies.349
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Bronchiolitis obliterans (BO) after HSCT is a rare and morbid
manifestation of cGVHD. Although lung biopsy is the gold standardfor diagnosis, the high complication rate restricts its use. There is
a lack of consensus in the literature concerning the diagnostic criteria
using non-invasive modalities. Thus, the NIH cGVHD consensus
project developed a definition for BO after HSCT based on clinical
characteristics of BO after lung transplant. This definition required
for non-pathologic diagnosis: a) Absence of infection, b) presence of
another cGVHD sign, c) FEV-1\75% and d) all 3 parameters to
confirm obstruction: 1) FEV1/FVC\0.7, 2) RV. 120%, and 3)
CT findings (table). To explore the sensitivity of these criteria, we
evaluated this definition in a group of patients with diagnoses of
cGVHD and BO (corroborated by NIH pulmonologists). Twenty-
four patients were identified; 1 was excluded for relapse and 1 for
lack of full PFTs. We then analyzed pulmonary and radiographic pa-
rameters of these 15 clinically identified cases of BO and 7 biopsy
proven cases. Only 18% (4/22) of patients met the NIH consensus
definition for a clinical diagnosis of BO, all of which had an
FEV1\ 55% suggestive of severe disease. While the majority of
the total had FEV1/FVC\0.7, using the slow vital capacity
(FEV1/SVC) enhanced sensitivity, capturing patients with airways
that collapse early, artificially lowering the FVC.
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Criteria86% 100%We then evaluated the patients that did not meet the new ratio cri-
teria (FEV1/SVC\0.7); all (6/6) had evidence of severe restriction
from scleroderma or myositis, thus masking the ratio evidence of ob-
struction. Because of their restrictive disease, the total lung capacity
(TLC) was decreased, also artificially lowering the RV. When RV/
TLC.120% of predicted was used with RV.120% predicted, 5/6
of these could be captured as BO and all had air trapping confirmed
on expiratory CT. Therefore, we amended the definition of BO to
confirm obstruction by either: 1) FEV1/SVC\0.7 OR air trapping
on CT with RV or RV/TLC . 120%. Using this amended defini-
tion, all but 1 case (biopsy proven) of our cohort could be captured
clinically, increasing our sensitivity from 18% to 95%. We therefore
present a modification of the NIH consortium criteria that our data
suggests enhances the sensitivity of this test in our cGVHD popula-
tion. These criteria will require further validation for integration
into future trials.
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